{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:23:53Z","timestamp":1787786633092,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most individuals are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective claims data analysis using the \u201cInstitute for Applied Health Research Berlin\u201d (InGef) Research Database, containing claims data from approximately 4 million individuals. In the period from 2012 to 2017 all women born in1989\u20131992, who were continuously insured between the age of 23\u201325\u2009years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated (women with diagnosis divided by all women).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2012 to 2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23\u201325 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12\u20131.49) birth cohort 1989 vs. 0.94% (0.79\u20131.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93\u20131.26) birth cohort 1989 vs. 0.71% (0.58\u20130.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76\u20131.07) birth cohort 1989 vs. 0.60% (0.48\u20130.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23\u20131.61) birth cohort 1989 vs. 1.31% (1.14\u20131.51) birth cohort 1992) and grade II (0.61% (0.49\u20130.75) birth cohort 1989 vs. 0.52% (0.42\u20130.65) birth cohort 1992) remained stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years in light of varying HPV vaccination coverage for newer birth cohorts is necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05002-w","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:04:14Z","timestamp":1587553454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Burden of HPV related anogenital diseases in young women in Germany \u2013 an analysis of German statutory health insurance claims data from 2012 to 2017"],"prefix":"10.1186","volume":"20","author":[{"given":"Miriam","family":"Reuschenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mihm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"W\u00f6lle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Maren","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"issue":"1","key":"5002_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s12879-017-2812-z","volume":"17","author":"Z Lyu","year":"2017","unstructured":"Lyu Z, Feng X, Li N, Zhao W, Wei L, Chen Y, Yang W, Ma H, Yao B, Zhang K, et al. Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):714.","journal-title":"BMC Infect Dis"},{"key":"5002_CR2","unstructured":"World Health Organization (WHO): Human papillomavirus (HPV) and cervical cancer. [https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer] Accessed 28 Mar 2019."},{"issue":"1","key":"5002_CR3","first-page":"2","volume":"1","author":"KP Braaten","year":"2008","unstructured":"Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008;1(1):2\u201310.","journal-title":"Rev Obstet Gynecol"},{"key":"5002_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/1471-2334-10-360","volume":"10","author":"AA Kraut","year":"2010","unstructured":"Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis. 2010;10:360.","journal-title":"BMC Infect Dis"},{"key":"5002_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2334-13-39","volume":"13","author":"H Patel","year":"2013","unstructured":"Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"5002_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12879-017-2663-7","volume":"17","author":"K Th\u00f6ne","year":"2017","unstructured":"Th\u00f6ne K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC Infect Dis. 2017;17(1):564.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"5002_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jcp.55.4.244","volume":"55","author":"FX Bosch","year":"2002","unstructured":"Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244\u201365.","journal-title":"J Clin Pathol"},{"key":"5002_CR8","volume-title":"Krebs in Deutschland f\u00fcr 2013\/2014","author":"Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland","year":"2017","unstructured":"Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland. Krebs in Deutschland f\u00fcr 2013\/2014. Berlin: Robert Koch-Institut; 2017."},{"key":"5002_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"S Hartwig","year":"2015","unstructured":"Hartwig S, Baldauf J-J, Dominiak-Felden G, Simondon F, Alemany L, de Sanjos\u00e9 S, Castellsagu\u00e9 X. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res. 2015;1:90\u2013100.","journal-title":"Papillomavirus Res"},{"issue":"3","key":"5002_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/LGT.0b013e31826f2b2b","volume":"17","author":"M Reuschenbach","year":"2013","unstructured":"Reuschenbach M, Roos J, Panayotopoulos D, Baldus SE, Schn\u00fcrch H-G, Berger A, Petry KU, D\u00fcrst M, Seiz M, von Knebel DM, et al. Characterization of squamous cell cancers of the vulvar anterior Fourchette by human papillomavirus, p16INK4a, and p53. J Low Genit Tract Dis. 2013;17(3):289\u201397.","journal-title":"J Low Genit Tract Dis"},{"key":"5002_CR11","unstructured":"European Medicines Agency: HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. [https:\/\/www.ema.europa.eu\/en\/documents\/referral\/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-pots_en.pdf] Accessed 15 Apr 2019."},{"key":"5002_CR12","first-page":"129","volume":"7","author":"Robert Koch-Institut","year":"2016","unstructured":"Robert Koch-Institut. Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2014. Epid Bull. 2016;7:129\u201342.","journal-title":"Epid Bull"},{"issue":"8","key":"5002_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"5002_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-9378-7-38","volume":"7","author":"B Serrano","year":"2012","unstructured":"Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjose S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.","journal-title":"Infect Agent Cancer"},{"issue":"45","key":"5002_CR15","first-page":"771","volume":"108","author":"M Wiese-Posselt","year":"2011","unstructured":"Wiese-Posselt M, Tertilt C, Zepp F. Vaccination recommendations for Germany. Dtsch Arztebl Int. 2011;108(45):771\u201380.","journal-title":"Dtsch Arztebl Int"},{"key":"5002_CR16","first-page":"97","volume":"23","author":"Robert Koch-Institut: Mitteilung der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut","year":"2007","unstructured":"Robert Koch-Institut: Mitteilung der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Impfung gegen humane Papillomaviren (HPV) f\u00fcr M\u00e4dchen von 12 bis 17 Jahren \u2013 Empfehlung und Begr\u00fcndung. Epid Bull. 2007;23:97\u2013106.","journal-title":"Epid Bull"},{"issue":"9","key":"5002_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00103-018-2791-2","volume":"61","author":"A Takla","year":"2018","unstructured":"Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, R\u00f6bl-Mathieu M, Terhardt M, van der Sande M, Wichmann O, Zepp F, Klug SJ. Background paper for the recommendation of HPV vaccination for boys in Germany. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2018;61(9):1170\u201386.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"5002_CR18","first-page":"233","volume":"26","author":"Robert Koch-Institut","year":"2018","unstructured":"Robert Koch-Institut. Wissenschaftliche Begr\u00fcndung f\u00fcr die Empfehlung der HPV-Impfung f\u00fcr Jungen im Alter von 9 bis 14 Jahren. Epid Bull. 2018;26:233\u201354.","journal-title":"Epid Bull"},{"issue":"6","key":"5002_CR19","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.4161\/hv.28450","volume":"10","author":"S Hense","year":"2014","unstructured":"Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729\u201333.","journal-title":"Hum Vaccin Immunother"},{"key":"5002_CR20","first-page":"1","volume":"2018","author":"Robert Koch-Institut","year":"2018","unstructured":"Robert Koch-Institut. Aktuelles aus der KV-Impfsurveillance \u2013 Impfquoten ausgew\u00e4hlter Schutzimpfungen in Deutschland. Epid Bull. 2018;2018:1.","journal-title":"Epid Bull"},{"key":"5002_CR21","volume-title":"Fact sheet on KiGGS Wave 1: German Health Interview and Examination Survey for Children and Adolescents \u2013 First follow-up interview 2009\u20132012","author":"Robert Koch-Institut","year":"2014","unstructured":"Robert Koch-Institut. Vaccination againsthuman papillomavirus (HPV) in girls. In:  Fact sheet on KiGGS Wave 1: German Health Interview and Examination Survey for Children and Adolescents \u2013 First follow-up interview 2009\u20132012; 2014."},{"issue":"1","key":"5002_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J. Characteristics and external validity of the German health risk institute (HRI) database. Pharmacoepidemiol Drug Saf. 2016;25(1):106\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"5002_CR23","first-page":"119","volume":"52","author":"A Agresti","year":"1998","unstructured":"Agresti A, Coull BA. Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions. Am Stat. 1998;52(2):119\u201326.","journal-title":"Am Stat"},{"key":"5002_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2334-14-87","volume":"14","author":"Y Delere","year":"2014","unstructured":"Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, Wichmann O, Kaufmann AM. Human papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis. 2014;14:87.","journal-title":"BMC Infect Dis"},{"key":"5002_CR25","unstructured":"National HPV Vaccination Program Register: National (Australia) HPV 3 dose vaccination coverage for females turning 15 years of age in 2015. [http:\/\/www.hpvregister.org.au\/site\/DefaultSite\/filesystem\/documents\/Coverage-Data\/2018\/Coverage%20by%20dose%202015%20-%20females.pdf] Accessed 13 May 2019."},{"issue":"1","key":"5002_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/OLQ.0b013e3182756efd","volume":"40","author":"RT Mikolajczyk","year":"2013","unstructured":"Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis. 2013;40(1):28\u201331.","journal-title":"Sex Transm Dis"},{"key":"5002_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2334-12-367","volume":"12","author":"KU Petry","year":"2012","unstructured":"Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Schulze-Rath R, Iftner T. Prevalence of low-risk HPV types and genital warts in women born 1988\/89 or 1983\/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis. 2012;12:367.","journal-title":"BMC Infect Dis"},{"key":"5002_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2334-13-135","volume":"13","author":"KU Petry","year":"2013","unstructured":"Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Luthge A, Grunwald E, Schulze-Rath R, Iftner T. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988\/89 or 1983\/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis. 2013;13:135.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"5002_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/sextrans-2014-051813","volume":"91","author":"EPF Chow","year":"2015","unstructured":"Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, Fairley CK. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214\u20139.","journal-title":"Sex Transm Infect"},{"issue":"3","key":"5002_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00404-014-3421-3","volume":"291","author":"S Geyer","year":"2015","unstructured":"Geyer S, Jaunzeme J, Hillemanns P. Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. Arch Gynecol Obstet. 2015;291(3):623\u20139.","journal-title":"Arch Gynecol Obstet"},{"key":"5002_CR31","unstructured":"Deutsches Institut f\u00fcr Medizinische Dokumentation und Information (DIMDI): ICD-10-GM - Versionsverlauf und Bekanntmachungen. [https:\/\/www.dimdi.de\/dynamic\/de\/klassifikationen\/icd\/icd-10-gm\/historie\/versionsverlauf\/] Accessed 15 Apr 2019."},{"key":"5002_CR32","unstructured":"GKV Spitzenverband: Fokus: Asylsuchende\/ Fl\u00fcchtlinge. [https:\/\/www.gkv-spitzenverband.de\/presse\/themen\/fluechtlinge_asylbewerber\/fluechtlinge.jsp] Accessed 22 Nov 2019."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05002-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05002-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05002-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T19:21:04Z","timestamp":1619032864000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05002-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5002"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05002-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12734\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12734\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12734\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12734\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used anonymized German claims data. Data contributing to the InGef Research Database are stored at a specialized data center according to \u00a7284 in combination with \u00a770 and \u00a771 Social Code Book (\u201cSozialgesetzbuch\u201d, SGB) V. Access to the data is restricted to health service research and is granted on a study by study basis from the InGef on behalf of the participating statutory health insurances. The data center is owned by statutory health insurances and provides data warehouse services. In the data center (acting as a trust center), data with respect to individual insured members and health care providers (e.g. physicians, practices, hospitals, pharmacies) are anonymized by coarsening or by removing individual variables. Since all patient-level data in the InGef Research Database are no longer social data according to \u00a7 67 Abs. 2 SGB X in combination with Art. 4 Nr. 1 of the General Data Protection Legislation (\u201cDatenschutz-Grundverordnung\u201d, DSGVO), institutional review board\/ethical approval and informed consent of the patient was not required. Furthermore, regions that are smaller than federal states or patient cohorts with less than 100 individuals were not analyzed in a granular way and patient counts below 5 were reported as \u201c<\u20095\u201d.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MR, SM, and RW are full time employees of MSD SHARP & DOHME GmbH. KS, CJ, and SB are full-time employees of Xcenda, acting as contractors of MSD SHARP & DOHME GmbH for the execution of this study. MH received honoraria as speaker and member of medical advisory boards from MSD Sharp & Dohme GmbH, Astra Zeneca, Gedeon Richter and honoraria as an author for Thieme and Springer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"297"}}